From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays
Core Technologies in Precision Oncology
This transformation has been driven by breakthroughs in genomic technologies, automation, bioinformatics, and a deeper understanding of cancer biology. At the core of precision oncology’s evolution lie three founda- tional technologies that are driving today’s commer- cialized clinical applications: quantitative PCR (qPCR), targeted next-generation sequencing (tNGS), and whole-genome sequencing (WGS). Each offers distinct advantages for specific clinical needs, and increasingly, developers are combining them to maximize diag- nostic power. 1 While other traditional (digital PCR) and emerging technologies continue to shape research and discovery in academic settings, these three remain central to current diagnostic offerings. This article explores the unique strengths, applica- tions, and considerations of each platform and how they can be strategically combined to drive the future of cancer diagnostics.
M olecular diagnostics are reshaping cancer care far beyond detection—they are rede- fining how we diagnose, monitor, and treat malignancies across the care continuum. Over the past two decades, the field has evolved from early PCR-based assays used in infectious disease and hereditary testing to advanced sequencing platforms capable of decoding entire cancer genomes.
qPCR: Speed, Simplicity, and Sensitivity Quantitative PCR (qPCR), also known as real-time PCR, is a molecular technique that amplifies and quantifies specific DNA sequences in real time. It remains the most accessible tool in the precision oncology toolbox. Known for its speed, sensitivity, and ease of use, qPCR is ideal for applications requiring rapid detection of known genetic mutations, such as EGFR in non-small cell lung cancer, BRAF in melanoma, or KRAS in colorectal cancer. It is widely used in FDA-approved
companion diagnostics to guide targeted therapies 2 ( Table 1 ). However, its limitations lie in its targeted nature: qPCR requires prior knowledge of the mutation being tested and cannot detect unknown variants or structural changes, making it less suitable for compre- hensive mutation profiling or monitoring evolving resistance mechanisms. 3 As a result, qPCR is often used as a frontline tool, followed by sequencing when deeper insight is required.
12 | GENengnews.com
Powered by FlippingBook